Press

Psychedelics Biotech Company, Awakn Life Sciences, Goes Public on the NEO Exchange

Jun 23 • 3 min read

Quick Take: Awakn Life Sciences debuted on the NEO exchange this morning. Awakn Life Sciences Corp, a biotechnology company with clinical operations that researches, develops, and delivers psychedelic medicines to treat addiction, has made its public markets debut today. Awakn is now available for trading on the NEO Exchange under the symbol AWKN. “Listing on the…

Red Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast Facility

Jun 22 • 3 min read

Quick Take: Red Light Holland has acquired 51% of Acadian Exotic Mushrooms Red Light Holland Corp. (CSE: TRIP), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market in the Netherlands, is pleased to announce that it has entered into a non-binding letter…

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Jun 18 • 2 min read

Quick Take: atai Life Sciences (Nasdaq: ATAI) has closed on their initial public offering. issuing 15,000,000 common shares at a price of $15/share atai Life Sciences B.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United…

Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta

Jun 17 • 2 min read

Quick Take: Mydecine has launched its machine learning drug discovery program at the University of Alberta. The program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them, allowing Mydecine to focus on the strongest potential therapeutics Mydecine Innovations Group Inc (NEO:MYCO) has launched its in-silico…

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

Jun 17 • 4 min read

Quick Take: MindMed has appointed Dr, Peter Bergethon to their scientific advisory board. Dr. Bergethon is an expert in neurology, digital medicine, and CNS drug development. MindMed (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435